Human papillomavirus (HPV) information needs: a theoretical framework

Laura A V Marlow, Jane Wardle, Nina Grant, Jo Waller

Abstract

Background With the introduction of human papillomavirus (HPV) testing and vaccination in the UK, health professionals will start to receive questions about the virus from their patients. This study aimed to identify the key questions about HPV that British women will ask when considering having an HPV test or vaccination.

Methods Face-to-face interviews were carried out with 21 women to discover what they wanted to know about HPV. A thematic framework approach was used to analyse the data and identify key themes in women’s HPV knowledge requirements.

Results Women’s questions about HPV fell into six areas: identity (e.g. What are the symptoms?), cause (e.g. How do you get HPV?), timeline (e.g. How long does it last?), consequences (e.g. Does it always cause cervical cancer?) and control-cure (e.g. Can you prevent infection?). In addition, they asked procedural questions about testing and vaccination (e.g. Where do I get an HPV test?). These mapped well onto the dimensions identified in Leventhal’s description of lay models of illness, called the ‘Common Sense Model’ (CSM).

Discussion and conclusions These results indicated that the majority of the questions women asked about HPV fitted well into the CSM, which therefore provides a structure for women’s information needs. The findings could help health professionals understand what questions they may be expected to answer. Framing educational materials using the CSM themes may also help health educators achieve a good fit with what the public want to know.

Keywords cervical cancer, HPV, lay models, qualitative research, sexual health

(Accepted 20 August 2008)

Background

Advances in medical science have demonstrated that infection with human papillomavirus (HPV) is the key factor in the aetiology of cervical cancer and genital warts. Technologies to test for the presence of the virus are now available and are being evaluated at selected sites in the UK. A prophylactic vaccine has also been developed and this will be offered to all girls aged 12–13 years in the UK from 2008. Progress in this field has been so rapid that diffusion of HPV information to the public has not kept pace with scientific advances. Most people have never heard of HPV and are unaware that cervical cancer has an infectious aetiology. However, with testing and vaccination becoming available, health professionals will start to get questions about the virus from patients. An understanding of what questions women may ask could help prepare health professionals for what they will have to explain. There is also an urgent need for public education materials (such as websites and leaflets) that women can be referred to for answers to their questions, helping them to make informed decisions about participation in testing and vaccination. Understanding what women want to know about HPV could help inform the content and structure of these materials.

Several studies in the USA and Australia have begun to identify the issues in HPV that women ask about. In 2003, staff from the American Social Health Association identified the most frequently asked questions about HPV and more recently several qualitative studies have identified key issues about HPV that both women and men want to know. There has been one study in the UK considering HPV-related information needs in a sample of women who had recently been screened. Women were recruited through cervical screening centres in England to take part in focus groups. After reading information about HPV, women discussed their responses and identified various unanswered questions. There has been a high level of consistency between the findings of these studies despite the different contexts that participants were recruited from. The most important issues about HPV seem to relate to transmission, prevalence, consequences, prevention and treatment.

HPV information should also be scientifically accurate and minimise any possible stigma that might be associated with the infection because of its sexually transmitted nature. Tristram used her clinical judgment to identify ten important points that addressed these criteria. These included the high prevalence of HPV, spontaneous clearance, that HPV may be present for some years before abnormalities arise, and that different HPV types cause cervical cancer and genital warts. Cuschieri et al. reviewed the existing literature on what the population want to know and what they should know with regard to HPV. They too focused on the importance of de-stigmatising HPV and highlighted the importance of emphasising its high prevalence and predominantly benign nature. They also noted the need to tell women that condoms are not always protective and that genital warts and cervical cancer are distinct consequences of HPV infection.
One aim of this study was to identify the questions that British women have about HPV. We also examined whether a theoretical structure widely used in the literature on lay models of illness would successfully frame the questions women ask about HPV. This has not been done in previous studies of HPV information needs. Leventhal’s ‘Common Sense Model’ (CSM) of illness representations has been successfully applied to a wide variety of illnesses. The theory posits that lay cognitive representations of illness fall into five dimensions: identity (labels/symptoms of the illness), perceived cause (determinants), controllability (prevention and treatment), consequences (to health and quality of life) and timeline (duration). The CSM’s primary application has been in relation to chronic diseases, but if the model represents a ‘natural’ cognitive structure of illness then the questions that women ask about a new infection such as HPV should map onto the CSM dimensions. If so, the CSM could also provide a useful framework around which to structure HPV information for the public.

**Methods**

**Participants**

Face-to-face, individual interviews were conducted with a sample of 21 women aged between 18 and 53 years. A convenience sample was recruited using a ‘snowballing’ technique. Interviews were carried out at University College London and women were reimbursed £20 for their time. The study was conducted in line with the University Research Ethics Committee guidelines, but we did not seek independent approval from the ethics board because the methods used fell within the exemption criteria.

**Procedure**

Women were asked to describe their background, giving details of their age, education, employment status, marital status and cervical screening history. They were then asked what they knew about cervical cancer and HPV. Because very few women had even heard of HPV, some basic facts were presented to women on a card at the start of the interview (Box 1). These facts were also read aloud by the interviewer. Women were then asked what additional information they would need to be sufficiently informed to make a decision about HPV testing or vaccination. Their questions were answered as the interview progressed and the interview ended when they were satisfied with the information they had received. Two of the authors (LM and JoW) each carried out one interview and the rest were conducted by the third author (NG). All interviewers were female.

**Analysis**

Interviews were recorded and transcribed verbatim. We used a thematic framework analysis, which allowed us to organise the data in a systematic and manageable way. After familiarisation with the transcripts, a framework was created based on the core themes that emerged from the interviews. Each question was entered into the thematic framework under one of these themes. This allowed for identification of specific questions within each theme.

**Results**

Characteristics of the study group are shown in Table 1. All participants were white except one Asian-British woman.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>18–25</td>
<td>9</td>
</tr>
<tr>
<td>26–33</td>
<td>4</td>
</tr>
<tr>
<td>34–41</td>
<td>5</td>
</tr>
<tr>
<td>42–49</td>
<td>2</td>
</tr>
<tr>
<td>50+</td>
<td>1</td>
</tr>
<tr>
<td>Education status</td>
<td></td>
</tr>
<tr>
<td>Degree level</td>
<td>16</td>
</tr>
<tr>
<td>A levels</td>
<td>5</td>
</tr>
<tr>
<td>Employment status</td>
<td></td>
</tr>
<tr>
<td>Employed (full-time)</td>
<td>6</td>
</tr>
<tr>
<td>Employed (part-time)</td>
<td>4</td>
</tr>
<tr>
<td>Homemaker (full-time)</td>
<td>3</td>
</tr>
<tr>
<td>Student</td>
<td>8</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
</tr>
<tr>
<td>Married/cohabiting</td>
<td>9</td>
</tr>
<tr>
<td>Single</td>
<td>10</td>
</tr>
<tr>
<td>Divorced/separated</td>
<td>2</td>
</tr>
<tr>
<td>Cervical screening history</td>
<td></td>
</tr>
<tr>
<td>Never screened</td>
<td>4</td>
</tr>
<tr>
<td>Yes, once</td>
<td>3</td>
</tr>
<tr>
<td>Yes, more than once</td>
<td>14</td>
</tr>
</tbody>
</table>

Participants were very interested in HPV, but the number of direct questions ranged from just five to 28 questions. Between them the 21 women generated 300 questions about HPV. Many of their questions were similar, and all questions could be classified under six themes. The first five themes were consistent with the illness representation component of Leventhal’s CSM. The themes have been labelled using terminology from this model as follows: identity (asymptomatic nature of HPV and its prevalence), cause (main cause and additional risk factors), timeline, consequences (cervical cancer, genital warts, social consequences) and cure-control (possible prevention, cervical screening, HPV testing, HPV vaccination). Women also had additional questions about the procedures for HPV testing and future options for vaccination, and these are presented as an additional theme. [NB. In the sections that follow, example questions are listed for each theme and the participant asking the question is indicated by a number.]

**Identity**

Most women wanted to know if there were any signs or symptoms relating to HPV. They asked about the prevalence of HPV, and once told that it is very common, they wanted to know why so many women become infected.

*Does HPV have any symptoms? (P3)*

*Is it really common in England? (P19)*
Cause
All women wanted to know the cause of HPV, and once told it was sexually transmitted, they asked if this was the only way to contract it. They asked many questions relating to additional risk factors (e.g. if HPV was more likely in a particular age group and whether having more sexual partners was associated with higher risk). Women asked if lifestyle factors such as diet or drinking alcohol increased risk of infection.

How do you contract HPV? (P2)
Can you catch HPV any other way? (P5)
Is HPV more common in younger people? (P5)
Are more promiscuous women at greater risk? (P3)
Does drinking increase your risk? (P10)

Timeline
Women were particularly interested in the time between contracting HPV and developing cervical cancer. Questions were raised about the potential for the virus to clear spontaneously and how long this process took.

How long does it take for HPV to become cervical cancer? (P3)
So can it clear by itself then? (P13)
For how long can the virus lie dormant? (P13)

Consequences
In relation to cervical cancer, women wanted to know how common it was for this to be the consequence of HPV, and whether cervical cancer could be caused by other things. They also wanted to know if HPV could cause any other cancers, if it had any effect on pregnancy, and if the virus had any other effects on the body. The possibility of cancer being related to genital warts was also raised.

How many cases of HPV become cervical cancer? (P4)
Is HPV the only cause of cervical cancer? (P5)
What other cancers are caused by a virus? (P3)
What about getting pregnant? (P15)
Does HPV have any other effects on your body? (P15)
Are genital warts and cancer related? (P14)

Younger women (i.e. those aged 18–25 years) asked many questions about the prevalence of cervical cancer and treatments available for the disease.

How many women get cervical cancer? (P1)
How is cervical cancer treated once you have it? (P5)

Consequences for men were frequently mentioned, including whether men are just carriers of the virus or are likely to experience harmful effects. The matter of disclosing an HPV diagnosis to a sexual partner was raised, which introduced the issue of indirect social and psychological consequences from the disclosure.

Can a man get HPV? (P20)
Does it have any effect on men? (P4)
If you test positive should you tell your partner? (P10)

Cure-control
Women asked how they could protect themselves and whether condoms were an effective way to reduce their risk. They also wanted to know if there was any treatment available for HPV, and requested more details about what was involved in the treatment of pre-cancerous cells. When it was explained that in most cases HPV clears spontaneously, women wanted to know how quickly this could happen and why it did not clear in all cases.

Is there any way to protect yourself against HPV? (P19)
Does using a condom protect you? (P1)
What kind of treatment is there for HPV? (P12)
What does treatment for cell changes involve? (P8)
How quickly does it get cleared? (P8)
Why do some people clear it with their immune system but others don’t? (P9)

The younger women (i.e. those aged 18–25 years) – who had no experience of cervical screening because screening in England begins at the age of 25 years – asked many questions about cervical screening, including the purpose of screening, the recommended frequency, and the age at which screening should be initiated.

How often do you go for screening? (P19)
What age do you start to go for screening? (P19)

Procedures: HPV testing/vaccination
Although the existence of HPV testing and vaccination would be included in the cure-control dimension, women in this sample were asked to imagine they were offered testing/vaccination, and this prompted a variety of additional procedural questions. Women wanted to know what the HPV test would involve, and the practicalities of the test including where it would be carried out, how long it would take to get results, and if it was included in screening for sexually transmitted infections (STIs). Several women also asked how an HPV test would be different from the current cervical screening procedures.

What does the [HPV] test involve? (P1)
Can you get it at the doctors? (P7)
How long would it take to find out the result? (P7)
Is HPV included in STI testing? (P21)
How would an HPV test differ from a smear test? (P20)

Women were extremely interested in the prospect of HPV vaccination and asked many questions about effectiveness, possible risks, mechanisms, research trials, likely coverage, and availability. They wanted to know how likely the vaccine was to provide full protection and if it would reduce deaths from cervical cancer to zero. They were concerned about adverse effects following the vaccination including possible side effects in the future. Women asked if the vaccine would be ‘a bit of the virus’ and if it was possible to get infected with the virus from the vaccine. They also asked if the vaccine would be only preventive or also therapeutic, and wondered whether it would be effective if the virus was ‘dormant’. The practicalities of vaccination (e.g. How many doses, whether a booster was required?) also attracted interest.

How effective is the vaccine? (P2)
What are the side effects of the vaccine? (P3)
What are the long-term effects of the vaccine? (P15)
How does the vaccine work, is it a bit of the virus? (P4)
Can you get the virus from the vaccine? (P18)
Is the vaccine for prevention or cure? (P17)
How many times would you have to have the vaccination? (P6)

Women had many questions about current vaccine trials, wanting to know details such as how long the trials had been underway, how the vaccine had been tested, and who it had been tested on. There was also interest in who had carried out the trials. Women wanted to know what exactly the vaccination would protect against, including if it would protect against all HPV types, genital warts and any other STIs. They asked questions about who the vaccine would be offered to, whether the vaccine would be just for girls, and if it would be targeted at a specific age group. They wanted to know when the vaccine would be available and how it would be offered [i.e. through general
In addition to general questions about HPV, women asked many specific procedural questions about HPV testing and vaccination. The younger women also asked questions about cervical cancer and screening, because at this age these details were also novel (women are not invited for cervical screening in England until they attain the age of 25 years). Context is likely to be very important in relation to what women want to know. Women who are thinking about vaccination for their daughter may focus on very different aspects compared with women who have received an abnormal smear result, or women who are simply interested in finding out more about HPV.

**Study limitations**

There are several limitations to this study. The analyses were based on interviews with predominantly white, well-educated women, and we cannot be sure that the same questions would arise in interviews with women from different backgrounds; however, we did achieve saturation in understanding the perceived information requirements of this group and the similarities between our results and those of Goldsmith et al. suggest the most important themes in questions about HPV are consistent across different samples of British women. It will be essential that public information about HPV is evaluated with women from a broader demographic sample to ensure that its content is appropriate for all women.

Women were encouraged to generate as many questions as they could in the framework of an interview, and they may have generated more questions than they would have asked in a more natural setting. We were particularly interested in questions about HPV in the context of vaccination or testing. As neither of these procedures are routinely available at present, we used a hypothetical methodology, asking women to ‘imagine you had been invited for a test or vaccine’, which is an imperfect substitute for testing reactions to an actual screening/vaccination invitation.

We also asked women to consider vaccination for themselves, despite the fact that women of this age are unlikely to be offered HPV vaccination. It may have been more pertinent to ask mothers about vaccination for their daughters or to ask adolescent girls (who will be offered that vaccination) what questions they have. Future work could explore whether the same questions would arise in these groups.

**Conclusions**

To date, no theoretical framework has been used to structure the questions women ask about HPV. In this qualitative study the questions women asked about HPV – an infection about which they previously knew very little – mapped well onto the framework of the illness representations approach (CSM), supplemented with procedural questions about vaccination and testing. This could provide a useful framework for information health professionals ought to be aware of in relation to patients' information needs. Framing information in this way could also provide an effective structure to help health educators present the scientific facts in a way that fits with what the public want to know.

**Statements on funding and competing interests**

**Funding** Laura Marlow, Jane Wardle and Jo Waller are funded by Cancer Research UK. Nina Grant is funded by ESRC/MRC. Funding for this work was provided by Sanofi Pasteur MSD.

**Competing interests** None identified.
References
Human papillomavirus (HPV) information needs: a theoretical framework

Laura A V Marlow, Jane Wardle, Jo Waller and Nina Grant

*J Fam Plann Reprod Health Care* 2009 35: 29-33
doi: 10.1783/147118909787072432

Updated information and services can be found at:
http://jfprhc.bmj.com/content/35/1/29

These include:

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/